Prof. He currently serves as the Vice President of Eastern Institute of Technology, NingBo, leading its new permanent campus planning and development as well as operations and administrative services of the Institute.

Prior to this appointment, Prof. He was the Senior Advisor to the President of The University of Hong Kong, along with the University’s first Chief Innovation Officer, Chairman of the Board and Managing Director of HKU Innovation Holdings Limited, and Board Member of The University of Hong Kong – Shenzhen Hospital. Prof. He has served many senior executive roles, including the Deputy Director and Senior Program Officer at the Bill & Melinda Gates Foundation, Senior Vice President and Global R&D Head at BGI, CEO of BGI America, Global Head of Human Biomarker Centers at GlaxoSmithKline, the Board Director of P4 Medicine Institute, USA, as well as the Chair Professor at University of Science and Technology of China.

Prof. He has extensive experience in international government-academia-industry collaborations, He led or participated in many high-tech investment projects, and global medical research and disease control projects in cooperation with government, NGOs, United Nations World Health Organization and other institutions. During his tenure at the Gates Foundation, Prof. Yiwu He was responsible for multiple global health programs including diagnostics, drug and vaccine development for infectious diseases and nutrition programs. He managed the Foundation’s investments in the areas including HIV, Tuberculosis, Pneumonia, Enteric Diarrhea, Polio and maternal/neonatal cares. These initiatives involved countries from Africa, Southeast Asia, to Europe and North America. In addition, Prof. He established and managed multiple R&D strategies and programs in China under the directions of Bill Gates. His efforts in China helped the advancements of R&D of China’s biotech industry and particularly led to the large-scale vaccine productions using modern international standards with WHO Prequalification in China. Prof. He was also involved in multiple new drug development programs during his career in the pharmaceutical industry, including five new drugs which have been approved for sale in the United States and other countries.

Prof. He obtained his Bachelor degree from Fudan University, Ph.D. degree from Boston University, executive MBA degree from Duke University, and was a post-doctoral fellow at Harvard Medical School.